Geographic Atrophy Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Ionis, IVERIC bio, Apellis, Annexon, Novartis, Astellas

November 07 21:55 2023
Geographic Atrophy Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Ionis, IVERIC bio, Apellis, Annexon, Novartis, Astellas
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 23+ key pharma and biotech companies are working on 25+ pipeline drugs in the Geographic Atrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Geographic Atrophy Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Geographic Atrophy Market. 

The Geographic Atrophy Pipeline report embraces in-depth commercial, regulatory, and Geographic Atrophy clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Geographic Atrophy drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Geographic Atrophy Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Geographic Atrophy treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Geographic Atrophy therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Geographic Atrophy companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Geographic Atrophy drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Geographic Atrophy therapeutic market.

Geographic Atrophy Therapeutics Landscape

There are approx. 23+ key companies developing therapies for Geographic Atrophy. Currently, IVERIC bio is leading the therapeutics market with its Geographic Atrophy drug candidates in the most advanced stage of clinical development.

Geographic Atrophy Companies Actively Working in the Therapeutic Market Include:

  • Ionis Pharmaceuticals

  • IVERIC bio

  • Apellis Pharmaceuticals, Inc.

  • NGM Biopharmaceuticals

  • Annexon Inc.

  • Genentech

  • Alexion AstraZeneca Rare Disease

  • ONL Therapeutics

  • Alkeus Pharmaceuticals

  • Regenerative Patch Technologies, LLC

  • Astellas Pharma Inc

  • Gemini Therapeutics

  • Boehringer Ingelheim

  • Cell Cure Neurosciences LTD

  • Stealth BioTherapeutics Inc.

  • Hemera Biosciences LLC

  • Gyroscope Therapeutics Limited

  • Eyevensys

  • Nanoscope Therapeutics, Inc.

  • Catalyst Biosciences

  • Novartis

And Many Others

Emerging and Marketed Geographic Atrophy Drugs Covered in the Report Include:

  • IONIS-FB-LRx: Ionis Pharmaceuticals

  • Zimura: IVERIC bio

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Geographic Atrophy Companies Working in the Market @

Analysis of Emerging Geographic Atrophy Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Geographic Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Geographic Atrophy Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Geographic Atrophy Treatment Patterns

4. Geographic Atrophy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Geographic Atrophy Late Stage Products (Phase-III)

7. Geographic Atrophy Mid-Stage Products (Phase-II)

8. Geographic Atrophy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Geographic Atrophy Discontinued Products

13. Geographic Atrophy Product Profiles

14. Major Geographic Atrophy Companies in the Market

15. Key Products in the Geographic Atrophy Therapeutics Segment

16. Dormant and Discontinued Products

17. Geographic Atrophy Unmet Needs

18. Geographic Atrophy Future Perspectives

19. Geographic Atrophy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Idiopathic Thrombocytopenic Purpura Market

“Idiopathic Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Idiopathic Thrombocytopenic Purpura market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Idiopathic Thrombocytopenic Purpura market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States